ABC Money
Home

Novartis says cancer drug Glivec had 94 pct US market share in July-August 2007


Published :
Wed, 12 Sep 2007 17:46
By : Agencies
Print this Story


AddThis Social Bookmark Button

ZURICH (Thomson Financial) - Novartis AG's blockbuster cancer drug Glivec had a 94 pct market share in the US during the months of July and August 2007, said the head of Novartis' oncology division David Epstein at the Pharma Brand and Business Review in East Hanover, New Jersey.

In 2006, Glivec had sales of 2.6 bln usd and Novartis forecasts combined full-year peak sales of Glivec and cancer drug Tasigna at 4 bln usd.

Novartis expects marketing approval for Tasigna from regulatory authorities in the US and Europe in the fourth quarter, and in the second half of 2008 in Japan.

Oncology drug Femara should develop into another blockbuster from 2008, said Epstein, adding that it is one of Novartis' ten fastest-growing products.

In other developments, Epstein said that blockbuster bone loss treatment Zometa has a market share of 75 pct, and he expects sales growth to accelerate from the second half of 2008 in spite of competition from Ibandronate, Clodronate and Pamidronate.

sarah.fenwick@thomson.com

sf/mas/ajb

COPYRIGHT

Copyright AFX News Limited 2007. All rights reserved.

The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.




Share on


 You Might Like
Novartis loses case in India over patent for anti-cancer drug Glivec
Novartis unlikely to appeal Indian patent ruling, Glivec decision outstanding
+
Novartis says oncology pipeline boasts 25 drug candidates in phase I, II UPDATE

Comment on this Article
Comment:
Title:
Name:
Please Enter
 
Here
  

 Search News

 Look For
Business
Credit cards
Finance
Loans
Money
Mortgages

 
 Stock Quotes *
SYMBOL
LAST
CHANGE
DOW JONES
10340.69
-107.24 ( -1.03 %)
NASDAQ
2792.28
22.57 ( 0.81 %)
FTSE 100
5741.15
38.78 ( 0.68 %)

SYMBOL ( 2012-01-19 )
LAST
CHANGE
STANDARD CHARTERED ( 11:35am )
1559.00
70.00 ( 4.76 %)
WOLSELEY PLC ( 11:35am )
2250.00
70.00 ( 3.20 %)
CARNIVAL ( 11:35am )
2017.00
46.00 ( 2.42 %)
LAND SECURITIES GROUP ( 11:35am )
679.50
36.50 ( 5.63 %)
WHITBREAD ( 11:35am )
1662.99
33.99 ( 2.09 %)

SYMBOL ( 2012-01-19 )
LAST
CHANGE
3M COMPANY ( 12:34pm )
85.78
0.71 ( 0.83 %)
BOEING CO ( 12:34pm )
75.70
0.64 ( 0.85 %)
JP MORGAN CHASE CO ( 12:34pm )
37.03
0.49 ( 1.33 %)
WAL MART STORES ( 12:34pm )
60.44
0.43 ( 0.72 %)
IBM ( 12:34pm )
181.50
0.43 ( 0.24 %)

SYMBOL ( 2012-01-19 )
LAST
CHANGE
F5 NETWORKS INC ( 12:11pm )
122.38
13.92 ( 11.80 %)
ICO GLOBAL COMM CL A ( 8:01pm )
99999999.99
9.37 ( 366.02 %)
PRICELINECOM INC ( 12:23pm )
525.40
6.57 ( 1.26 %)
AMAZONCOM INC ( 12:04pm )
195.65
6.21 ( 3.25 %)
MILLICOM INTERNATIONAL CELLULAR SA ( 4:00pm )
110.18
4.82 ( 4.43 %)

Gainers & Losers
Dow Jones
Euro Stoxx 50
FTSE 100
FTSE 250
FTSE AIM
FTSE ALL
Nasdaq

 Portfolio Manager

You must log in to access this area of the site. If you are not a registered user click here to sign up for instant access!


 Finance Explained

Money making ideas

Save money

Money management
Savings accounts
Investing money
Share dealing
Stock broker
Forex currency trading
Pension plans
Functions of Money

(c) 2007 ABCmoney.co.uk, All Rights Reserved
*ABCMoney.co.uk does not guarantee the accuracy of any share prices or stock quotations displayed. These are not real time quotes; all are delayed by at least twenty minutes and are for information purposes only.